Supplementation of a Leucine-Enriched Dairy Protein Blend

June 18, 2024 updated by: Stuart Phillips, McMaster University

Supplementation of a Leucine-Enriched Dairy Protein Blend: Effects on Plasma Amino Acids in Older Adults

It is well known that dietary protein is a powerful transient stimulator of the muscle protein synthetic rate (MPS) whereby changes in MPS in response to feeding may be regulated by specific downstream target proteins of mammalian target of rapamycin signaling, such as S6K1, rpS6, and eIF2B. A meal deficient in protein, however, does not increase the rate of MPS because a rise in the bioavailability of amino acids does not occur. In addition, the source of dietary proteins has been shown to impact postprandial blood levels of amino acids. The concept that certain types of proteins are "fast acting" or "slow acting" has been shown to affect the postprandial profile of amino acids appearing in the systemic circulation. Native whey and micellar casein are both dairy proteins that contain a similar amount of essential (EAA), but blood EAA levels increase faster and to a higher level after the consumption of whey protein. Differences in gastric emptying, digestion and absorption kinetics between micellar casein and native whey are the underlying factors. Nonetheless, micellar casein protein has been shown to protract MPS in humans. Despite the significant amount of information gained with respect to both of these protein sources, the effects of combinatorial formulations on the postprandial profile of amino acids appearing in the blood is less well known. The purpose of the present study is to determine post-ingestion aminoacidemia, glycemia, and insulinemia from a specially formulated dairy protein blend.

Study Overview

Status

Completed

Conditions

Detailed Description

Experimental approach:

8 participants will be included in this study. Each participant will consume the supplement only once in a randomized fashion during three separate visits and there will be approximately 1 week between each visit.

Standardized meal:

Participants will be provided a standardized diet one day prior to experimentation. When performing research involving human metabolism it is important that the participants be tested in a weight-stable state. Therefore, the investigators will estimate the participants resting energy expenditure using a widely reference prediction formula, known as the Harris-Benedict equation. This formula takes into account gender, body mass, height, age, and self-reported activity level. Once resting energy expenditure is calculated the investigators will provide each participant with a pre-packaged standardized diet for the day prior to the experiment that is designed to ensure a sufficient energy balance.

Dual Energy X-Ray Absorptiometry (DXA) Scans:

DXA scans will be used to determine the participants body composition. The DXA procedures use a small amount of radiation to determine how much fat, bone, and lean mass the participants have in their body. The procedure takes approximately seven minutes and involves the participants lying still on an open bed while the sensor passes over the participants body.

Arterialized blood sampling:

All blood sampling will be achieved through an intravenous indwelling cannula. This method provides the least trauma to the participant when repeated blood sampling is required and is convenient for the investigators. In theory, repeated needle sticks may stress the participant thereby increasing sympathetic nervous system activity, thus causing changes in metabolism. Additionally, another potential drawback from venous blood sampling is the influence by regional tissue specific metabolism, thereby making it difficult to interpret whole-body metabolism on the basis of metabolites measured in venous blood. Therefore, arterial blood sampling is deemed the ideal method for metabolic studies. Arterial cannulation, however, may be unethical for research purposes due to increased risk of complications, such as damage to the arterial wall, thrombosis, and clot formation, all of which may cause death. Arterializing the blood being sampled can be achieved through heating either the superficial antecubital vein or dorsal hand vein with a heating blanket or specialized heat box. By doing so, blood flow increases as a result of vasodilatation of vessels in the arms skeletal musculature, as well as arteriovenous anastomoses in skin. Due to the increased blood flow and negligible muscle mass at the hand and elbow, results in venous blood being similar in composition to an arterial sample. This method is a widely used surrogate for safe direct arterial blood sampling. Once arterialized blood samples are obtained they will be preserved and used in analyses. The investigators will utilize heating blankets (Theratherm Large Digital Moist Heat Pad [14" x 27"]) to arterialize the blood samples and an infrared thermometer (Nubee, NUB8380) to determine the skin temperature (45-68∘C) prior to drawing the participant's blood.

Per-protocol conditions will include:

Consumption of a standardized meal the evening prior to each trial and consistent exercise/activity 2d before each trial There will be ~1wk between trials (washout periods) Blood samples will be analyzed for plasma amino acids, glucose, and insulin.

Experimental Interventions (randomized order):

  1. Participants will consume a Low Protein Containing Breakfast (10% of the Acceptable Macronutrient Distribution Range according to the Food and Nutrition Board of the Institute of Medicine) and 2 hours later the participants will consume 17g of a leucine enriched whey protein- hydrolyzed whey protein-micellar casein blend (50:43:7 whey:hydrolyzed-whey:casein) containing 600 IU Vitamin D and 3.5g leucine
  2. Participants will consume a High Protein Containing Breakfast (25% of the Acceptable Macronutrient Distribution Range according to the Food and Nutrition Board of the Institute of Medicine)
  3. Participants will consume a Low Protein Containing Breakfast (10% of the Acceptable Macronutrient Distribution Range according to the Food and Nutrition Board of the Institute of Medicine)

Proteins were provided by Covance Laboratories, Inc. owned by Eurofins.

The whey protein and micellar casein are milk proteins derived from cow's milk. The participants will consume the 17g of protein contained in a semi-solid bar equal to ∼40g, which is the size of a typical sports recovery bar.

Sample size and data analyses:

The sample size was determined by a statistical power analysis (G*Power 3.1 software, version 3.1.9, 2014) that revealed a large effect size. This study was powered on the basis of previous studies. Thus, a total of 8 (n = 8/group) participants will be used in analyses. See Below:

Analysis: A priori: Compute required sample size ANOVA: Repeated measures, within-between interaction Input Effect size f = 0.5 α err prob = 0.05 Power (1-β err prob) = 0.95 Number of groups = 3 Number of measurements = 14 Corr. Among rep. measures = 0.5 Nonsphericity correction ε = 1 Output Noncentrality parameter ƛ = 63 Critical F = 1.6380186 Numerator df = 26 Denominator df = 78 Total sample = 9 Actual power = 0.997

Study Type

Observational

Enrollment (Actual)

8

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Ontario
      • Hamilton, Ontario, Canada, L8S 4K1
        • Exercise Metabolism Research Laboratory, McMaster Univeristy

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

65 years and older (Older Adult)

Accepts Healthy Volunteers

N/A

Sampling Method

Non-Probability Sample

Study Population

Healthy Older Adults

Description

Inclusion Criteria:

  • 8 participants will be included in this study. Each participant will consume the supplement only once in a randomized fashion during one of three separate visits and there will be approximately 1 week between each visit. In order to participate in this study, each participant must be male or female, 65 years or older (inclusive) and cannot be a smoker or user of tobacco products.

Exclusion Criteria:

  • The exclusion requirements for this study include the following conditions:

    • Take any analgesic or anti-inflammatory drugs(s), prescription or non-prescription, chronically will be excluded. However, a washout period of 4 weeks will be suitable for participation.
    • A history of neuromuscular problems or muscle and/or bone wasting diseases
    • Any acute or chronic illness, cardiac, pulmonary, liver, or kidney abnormalities, uncontrolled hypertension, insulin- or non-insulin dependent diabetes or other metabolic disorders-all ascertained through medical history screening questionnaires
    • Use medications known to affect protein metabolism (i.e. corticosteroids, non-steroidal anti-inflammatories, or prescription strength acne medications)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Supplementation with Enriched Protein®
Participants will consume a low protein containing breakfast and 2 hours later will consume the enriched protein supplement
This product contains high quality bovine milk proteins enriched with additional leucine.
Low protein breakfast
No supplementation
High protein breakfast
No supplementation

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Easy-fast amino acid sample testing kit for gas chromatography mass spectrometry
Time Frame: 375 minutes
plasma amino acid concentrations
375 minutes

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Hexokinase/G-6-PDH methodology
Time Frame: 375 minutes
plasma glucose concentrations
375 minutes
Chemiluminescent Microparticle Immunoassay
Time Frame: 375 minutes
plasma insulin concentrations
375 minutes
Visual Analog Scale Questionnaires for food sensory perception desire to eat
Time Frame: Average score across 13 measurements
Units on a 100mm Paper Scale, 0mm = lowest score and 100mm = highest score
Average score across 13 measurements
Visual Analog Scale Questionnaires for food sensory perception for hunger
Time Frame: Average score across 13 measurements
Units on a 100mm Paper Scale, 0mm = lowest score and 100mm = highest score
Average score across 13 measurements
Visual Analog Scale Questionnaires for food sensory perception for fullness
Time Frame: Average score across 13 measurements
Units on a 100mm Paper Scale, 0mm = lowest score and 100mm = highest score
Average score across 13 measurements
Visual Analog Scale Questionnaires for food sensory perception for thirst
Time Frame: Average score across 13 measurements
Units on a 100mm Paper Scale, 0mm = lowest score and 100mm = highest score
Average score across 13 measurements
Visual Analog Scale Questionnaires for food sensory perception for how much food could be eaten
Time Frame: Average score across 13 measurements
Units on a 100mm Paper Scale, 0mm = lowest score and 100mm = highest score
Average score across 13 measurements
Visual Analog Scale Questionnaires for food sensory perception for liking or disliking of food
Time Frame: Average score across 13 measurements
Units on a 100mm Paper Scale, 0mm = worst score and 100mm = best score
Average score across 13 measurements
Visual Analog Scale Questionnaires for food sensory perception for visual appeal
Time Frame: Average score across 2 measurements
Units on a 100mm Paper Scale, 0mm = worst score and 100mm = best score
Average score across 2 measurements
Visual Analog Scale Questionnaires for food sensory perception for smell
Time Frame: Average score across 2 measurements
Units on a 100mm Paper Scale, 0mm = worst score and 100mm = best score
Average score across 2 measurements
Visual Analog Scale Questionnaires for food sensory perception for taste
Time Frame: Average score across 2 measurements
Units on a 100mm Paper Scale, 0mm = worst score and 100mm = best score
Average score across 2 measurements
Visual Analog Scale Questionnaires for food sensory perception for aftertaste
Time Frame: Average score across 2 measurements
Units on a 100mm Paper Scale, 0mm = worst score and 100mm = best score
Average score across 2 measurements
Visual Analog Scale Questionnaires for food sensory perception for pleasantness
Time Frame: Average score across 2 measurements
Units on a 100mm Paper Scale, 0mm = worst score and 100mm = best score
Average score across 2 measurements
Height in meters
Time Frame: One measurement at baseline
Stadiometer
One measurement at baseline
Weight in kilograms
Time Frame: One measurement at baseline
Physician scale
One measurement at baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Stuart M Phillips, PhD, McMaster University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 28, 2018

Primary Completion (Actual)

December 1, 2019

Study Completion (Actual)

June 1, 2020

Study Registration Dates

First Submitted

October 16, 2018

First Submitted That Met QC Criteria

October 18, 2018

First Posted (Actual)

October 19, 2018

Study Record Updates

Last Update Posted (Actual)

June 20, 2024

Last Update Submitted That Met QC Criteria

June 18, 2024

Last Verified

June 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • 2502

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy

Clinical Trials on Enriched Protein®

Subscribe